Pharmaceuticals
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
SINGAPORE, Nov. 26, 2024 /PRNewswire/ -- QDX proudly announces that the team led by its co-founder, Associate ProfessorGiuseppe Barca, has been honoured with the 2024 ACM Gordon Bell Prize, often referred to as the "Nobel Prize of high-performance computing." This accolade recognizes their ground...
2024-11-26 18:49
9340
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
* Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC. * Updated results of elacestrant in combination with abemaciclib show favorable efficacy regardless of theESR1 mutation status, with a manageable and predictable safet...
2024-11-26 17:16
3102
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed M...
2024-11-25 08:37
4149
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
SAN FRANCISCO and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-11-25 08:30
3689
ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection
SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infec...
2024-11-25 08:18
3209
SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy (SCG101) at the AASLD Liver Meeting 2024
SINGAPORE, Nov. 25, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, announced late-breaking data from its Phase 1 trial of SCG101, a first-in-class autolog...
2024-11-25 08:01
2026
FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer
NANJING, China, Nov. 22, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global intellectual property rights for the treatment of neuroendo...
2024-11-22 16:00
7970
Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity
SHANGHAI, Nov. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that data on its critical-care, anti...
2024-11-22 12:14
3249
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
ROCKVILLE, Md. and SUZHOU, China, Nov. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, announced today that findings from a ph...
2024-11-22 10:27
3128
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including$420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead...
2024-11-21 06:00
2561
GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products
PLANTATION, Fla., Nov. 21, 2024 /PRNewswire/ -- GBI Biomanufacturing (GBI), one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP)services, to include automated sterile fill and finish capabilit...
2024-11-21 01:00
1717
Samsung Biologics signs manufacturing deal with European pharmaceutical company
* The company will provide manufacturing services through 2031 in deals worth overUSD 668 million * Samsung Biologics' cumulative contract value for 2024 surpasses USD 4 billion with latest deals INCHEON, South Korea, Nov. 20, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global ...
2024-11-20 07:23
2502
Say Hello to 3.0: Datarithm Releases Latest Version of Inventory Management Solution
SYRACUSE, N.Y., Nov. 19, 2024 /PRNewswire/ -- In a landscape marked by intense competition, rising costs, and stringent regulatory requirements, independent pharmacies face an array of challenges that threaten their viability and success. Today, Datarithm® is proud to announce a solution to these...
2024-11-19 22:00
1638
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to suppor...
2024-11-19 19:30
3396
Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea's Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has received full appro...
2024-11-19 07:40
2770
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
MELBOURNE, Australia, Nov. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nucl...
2024-11-19 06:24
2740
VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
SHANGHAI and BOSTON, Nov. 18, 2024 /PRNewswire/ -- VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), today announced it has entered into an agreement with Avenzo Therapeutics, Inc. (Avenzo)...
2024-11-18 21:01
2106
New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership withHealthcare Executi...
2024-11-18 16:00
2019
Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions
* Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering * Robust and sustainable treatment effects support at least bi-annual dosing regimen * Best-in-class potential of novel PC...
2024-11-18 09:00
3569
Boehringer Ingelheim Commits to Veeva Vault CRM
Top biopharma company selects the next generation of CRM for life sciences as
its commercial foundation for future expansion and launches
SINGAPORE, Nov. 18, 2024 /PRNewswire/ -- Veeva Systems
2024-11-18 09:00
2868
Week's Top Stories
Most Reposted
Global virtual travel card program launched by Visa and Trip.com to make travel payments simpler and more seamless in Asia Pacific
[Picked up by 330 media titles]
2026-03-11 11:08PDG Targets USD 5 Billion Debt Raise
[Picked up by 295 media titles]
2026-03-11 10:00The Mastercard Collection: Savor the Extraordinary with Mastercard's Asia Gourmet Circle Program
[Picked up by 295 media titles]
2026-03-12 09:00TelkomMetra Streamlines Business Portfolio, AdMedika Group Poised to Enter a New Growth Phase on Regional Level Under Fullerton Health
[Picked up by 295 media titles]
2026-03-09 21:36
Progress Software Highlights Load Balancing as a Strategic Imperative for APAC Digital Infrastructure Resilience
[Picked up by 290 media titles]
2026-03-10 09:00
Most Read
Say Goodbye to Expensive Subscriptions, Hello to 4K: the All-in-One XbotGo Falcon AI Sports Camera Now Available for Global Public Sale
2026-03-06 23:20
7603
A French Electronic Storm is Brewing Over Victoria Harbour: DJ Snake to Headline French May Arts Festival 2026
2026-03-06 23:22
7120
CARsgen Therapeutics Announces 2025 Annual Results
2026-03-06 20:03
6691
